FHTX (Foghorn Therapeutics) 3-Month Share Buyback Ratio : 0.00% (As of Dec. 2024 )

View and export this data going back to 2020. Start your Free Trial

What is Foghorn Therapeutics 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Foghorn Therapeutics's current 3-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of Foghorn Therapeutics's 3-Month Share Buyback Ratio

For the Biotechnology subindustry, Foghorn Therapeutics's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Foghorn Therapeutics's 3-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Foghorn Therapeutics's 3-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Foghorn Therapeutics 3-Month Share Buyback Ratio Calculation

Foghorn Therapeutics's 3-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

3-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Sep. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Sep. 2024 )
	=	(55.593	-	55.594)	/	55.593
	=	-0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foghorn Therapeutics (NAS:FHTX) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Foghorn Therapeutics 3-Month Share Buyback Ratio Related Terms

Foghorn Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foghorn Therapeutics Inc (NAS:FHTX) » Definitions » 3-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Technology Square, Suite 700, Cambridge, MA, USA, 02139

Website

https://www.foghorntx.com

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Executives

Carlos Costa	officer: Chief People Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Steven F. Bellon	officer: See Remarks	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Fanny Cavalie	officer: Chief Strategy/Bus Ops Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Alfonso Quintas Cardama	officer: Chief Medical Officer	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Samuel Agresta	officer: Chief Medical Officer	784 MEMORIAL DR., CAMBRIDGE MA 02139
Lynch Thomas J. Jr.	director	800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Michael Lacascia	officer: Chief Legal Officer	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Carl Decicco	officer: Chief Scientific Officer	100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Abu Dhabi Investment Authority	10 percent owner	211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000
Platinum International Investment Holding Rsc Ltd	10 percent owner	26TH FLOOR, AL KHATEM TOWER, ADGM SQUARE, PO BOX 25642, AL MARYAH ISLAND, ABU DHABI C0 NA
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Jose Baselga	director	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139